COVID-19 in an international European liver transplant recipient cohort.

Details

Serval ID
serval:BIB_AD0AF3B9E949
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
COVID-19 in an international European liver transplant recipient cohort.
Journal
Gut
Author(s)
Becchetti C., Zambelli M.F., Pasulo L., Donato M.F., Invernizzi F., Detry O., Dahlqvist G., Ciccarelli O., Morelli M.C., Fraga M., Svegliati-Baroni G., van Vlierberghe H., Coenraad M.J., Romero M.C., de Gottardi A., Toniutto P., Del Prete L., Abbati C., Samuel D., Pirenne J., Nevens F., Dufour J.F.
Working group(s)
COVID-LT group
Contributor(s)
Colledan M., Fagiuoli S., Camagni S., Delwaide J., Vitale G., Moradpour D., Pascual M., Allegrini G., Tarsetti F., Giustizieri U., Rota L., Artru F., Saouli A.C., Burra P., Gambato M., Scalera I., Petridis I., Marques H.P., Welker M.W.
ISSN
1468-3288 (Electronic)
ISSN-L
0017-5749
Publication state
Published
Issued date
10/2020
Peer-reviewed
Oui
Volume
69
Number
10
Pages
1832-1840
Language
english
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Abstract
Knowledge on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant recipients is lacking, particularly in terms of severity of the disease. The aim of this study was to describe the demographic, baseline clinical characteristics and early outcomes of a European cohort of liver transplant recipients with SARS-CoV-2 infection.
We conducted an international prospective study across Europe on liver transplant recipients with SARS-CoV-2 infection confirmed by microbiological assay during the first outbreak of COVID-19 pandemic. Baseline characteristics, clinical presentation, management of immunosuppressive therapy and outcomes were collected.
57 patients were included (70% male, median (IQR) age at diagnosis 65 (57-70) years). 21 (37%), 32 (56%) and 21 (37%) patients had one cardiovascular disease, arterial hypertension and diabetes mellitus, respectively. The most common symptoms were fever (79%), cough (55%), dyspnoea (46%), fatigue or myalgia (56%) and GI symptoms (33%). Immunosuppression was reduced in 22 recipients (37%) and discontinued in 4 (7%). With this regard, no impact on outcome was observed. Forty-one (72%) subjects were hospitalised and 11 (19%) developed acute respiratory distress syndrome. Overall, we estimated a case fatality rate of 12% (95% CI 5% to 24%), which increased to 17% (95% CI 7% to 32%) among hospitalised patients. Five out of the seven patients who died had a history of cancer.
In this European multicentre prospective study of liver transplant recipients, COVID-19 was associated with an overall and in-hospital fatality rate of 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. A history of cancer was more frequent in patients with poorer outcome.
Keywords
Aged, Betacoronavirus, Cohort Studies, Coronavirus Infections/diagnosis, Coronavirus Infections/epidemiology, Coronavirus Infections/therapy, Europe, Female, Hospitalization, Humans, Liver Diseases/mortality, Liver Diseases/surgery, Liver Diseases/virology, Liver Transplantation, Male, Middle Aged, Pandemics, Pneumonia, Viral/diagnosis, Pneumonia, Viral/epidemiology, Pneumonia, Viral/therapy, Prospective Studies, Survival Rate, chronic liver disease, infectious disease, orthotopic liver transplantation
Pubmed
Web of science
Open Access
Yes
Create date
03/07/2020 19:22
Last modification date
07/01/2021 7:26
Usage data